Literature DB >> 21658313

Characteristics of patients with respiratory allergy in France and factors influencing immunotherapy prescription: a prospective observational study (REALIS).

M Migueres1, J-F Fontaine, T Haddad, M Grosclaude, F Saint-Martin, D Bem David, B Crestani.   

Abstract

To describe the sensitization profile of respiratory allergies in France, identifying factors influencing the prescription of allergen immunotherapy (AIT) [Transversal phase (T)], and assess treatment efficacy, tolerability, compliance and satisfaction [Longitudinal phase (L)]. French allergists (600) and pneumo-allergists (600) were offered participation and asked to recruit the first 20 new patients with allergic rhinitis (AR) and/or asthma, consulting for a first time allergy check-up with skin prick-test (T), and 5 patients sensitized to pollens (skin test and/or specific IgE) for whom SLIT with pollens was prescribed (L). In the T phase, 2,714 patients were recruited by 169 specialists, mostly allergists (76.5%). The majority (98%) suffered from AR, alone (57.7%) or with asthma (40.3%) and 80.3% suffered from moderate-to-severe rhinitis, mostly persistent (65.8%). Asthma, when present, was mostly intermittent (63.7%) or mild persistent (20.1%). Sensitization to house dust mites was the most common (64.5%), followed by grass pollens (61.5%), tree pollens (41.6%) and cat danders (30.5%). Poly-sensitization was seen in 73.6% of patients. AIT, mostly sublingual, was recommended in 55.6% of the patients, mostly (78.1%) because of insufficient control with symptomatic treatments. The overall impact of symptoms on QOL, positive skin test to grass pollens, ocular pruritus and/or nasal obstruction and moderate-to-severe rhinitis were significant predictors of SLIT prescription. Poly-sensitization or concomitant asthma were not seen as deterrents. Most patients consulting a specialist for allergy testing suffer from moderate-to-severe rhinitis. Treatment in current practice includes immunotherapy in half of the patients, and follows ARIA recommendations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21658313     DOI: 10.1177/039463201102400212

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  5 in total

Review 1.  Will sublingual immunotherapy offer benefit for asthma?

Authors:  Carlos E Baena-Cagnani; Désirée Larenas-Linnemann; Alvaro Teijeiro; Giorgio Walter Canonica; Giovanni Passalacqua
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

2.  "The value of pre- and co-seasonal sublingual immunotherapy in pollen-induced allergic rhinoconjunctivitis".

Authors:  Pascal Demoly; Moises A Calderon; Thomas B Casale; Hans-Jørgen Malling; Ulrich Wahn
Journal:  Clin Transl Allergy       Date:  2015-05-04       Impact factor: 5.871

Review 3.  Types of sensitization to aeroallergens: definitions, prevalences and impact on the diagnosis and treatment of allergic respiratory disease.

Authors:  Michel Migueres; Ignacio Dávila; Franco Frati; Angel Azpeitia; Yasmine Jeanpetit; Michèle Lhéritier-Barrand; Cristoforo Incorvaia; Giorgio Ciprandi
Journal:  Clin Transl Allergy       Date:  2014-05-01       Impact factor: 5.871

Review 4.  Management of the polyallergic patient with allergy immunotherapy: a practice-based approach.

Authors:  Pascal Demoly; Giovanni Passalacqua; Oliver Pfaar; Joaquin Sastre; Ulrich Wahn
Journal:  Allergy Asthma Clin Immunol       Date:  2016-01-11       Impact factor: 3.406

5.  Food and Aeroallergen Sensitization in IgE -Mediated Asthma in Egypt.

Authors:  Abdellah H K Ali
Journal:  Open Respir Med J       Date:  2021-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.